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Abstract: In this study, a series of twenty-five ring-substituted 4-arylamino-7-
chloroquinolinium chlorides were prepared and characterized. The compounds were tested 
for their activity related to inhibition of photosynthetic electron transport (PET) in spinach 
(Spinacia oleracea L.) chloroplasts and also primary in vitro screening of the synthesized 
compounds was performed against mycobacterial species. 4-[(2-Bromophenyl)amino]-7-
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chloroquinolinium chloride showed high biological activity against M. marinum, M. kansasii,  
M. smegmatis and 7-chloro-4-[(2-methylphenyl)amino]quinolinium chloride demonstrated 
noteworthy biological activity against M. smegmatis and M. avium subsp. paratuberculosis. 
The most effective compounds demonstrated quite low toxicity (LD50 > 20 μmol/L) against 
the human monocytic leukemia THP-1 cell line within preliminary in vitro cytotoxicity 
screening. The tested compounds were found to inhibit PET in photosystem II. The PET-
inhibiting activity expressed by IC50 value of the most active compound 7-chloro-4-[(3-
trifluoromethylphenyl)amino]quinolinium chloride was 27 μmol/L and PET-inhibiting 
activity of ortho-substituted compounds was significantly lower than this of meta- and 
para-substituted ones. The structure-activity relationships are discussed for all compounds. 
Keywords: 4-arylamino-7-chloroquinolines; photosynthetic electron transport inhibition; 
spinach chloroplasts; in vitro antimycobacterial activity; in vitro cytotoxicity;  
structure-activity relationships 
 
1. Introduction 
The increasing incidences of tuberculosis (TB), the number of cases of multi-drug-resistant strains 
of Mycobacterium tuberculosis (MDR-TB) and infections by non-tuberculous mycobacteria (NTM) 
that are connected with the increase of the number of immunocompromised patients and evolving 
resistance mycobacterial species to antimycobacterial chemotherapeutics make the discovery of new 
molecular scaffolds a priority [1–4]. 
The genus Mycobacterium consists of a closely related group of fast and slow-growing species, 
some of which are highly pathogenic. For example, M. tuberculosis causes one of the most serious 
human infections (tuberculosis). Difficulties should be considered while studying M. tuberculosis–
especially a slow growth rate and the requirement for stringent containment facilities. Therefore 
surrogate model strains are commonly used in laboratory studies. M. smegmatis is an ideal 
representative of a fast-growing non-pathogenic microorganism particularly useful in studying basic 
cellular processes of special relevance to pathogenic mycobacteria. Additionally, M. marinum is very 
closely related to M. tuberculosis and causes TB-like infections in poikilothermic organisms, 
especially frogs and fish. M. marinum therefore, is a good surrogate model due to its lower risk for 
laboratory workers, genetic relatedness and similar pathology to human TB [5–7]. 
Because of the high profile of M. tuberculosis, the pathogenic role of other NTM in humans was 
overshadowed for a long time. For example, M. kansasii, (one of the most virulent of the NTM), 
causes non-tuberculous mycobacterial lung infections which are increasingly common and can be 
indistinguishable from tuberculosis [8]. Accordingly, it is appropriate to extend the search for novel 
anti mycobacterials outside of the TB complex. 
Quinoline derivatives can be classified as antimycobacterial chemotherapeutics [9] and also drug 
design and development of other quinoline-based compounds is in progress [10–18]. In an excellent 
review by Janin hypotheses are suggested that quinoline-based derivatives can act similarly as 
pyrazinamide, interfere with the mycobacterial proton pump F0F1H+ATPase, D-alanine-D-alanine 
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ligase, biosynthesis of amino acids or nucleic acids [10]. A number of various quinoline analogues 
were found as inhibitors of kinases [19]. Recently various studies were published dealing with 
understanding the systems for Ser/Thr and Tyr protein phosphorylation in M. tuberculosis and it was 
found that these kinases appear to regulate diverse processes including cell division and molecular 
transport. These facts can result in research of new antimycobacterials [20–26]. 
It was found that quinoline-like compounds exhibit herbicidal activity [15–17,27–33]. Over 50% of 
commercially available herbicides act by reversible binding to photosystem II (PS II), a membrane-
protein complex in the thylakoid membranes, which catalyses the oxidation of water and the reduction 
of plastoquinone [34] and thereby inhibit photosynthesis [35–37]. 
Both pharmaceuticals and pesticides are designed to target particular biological functions, and in 
many cases they target similar processes or have similar molecular sites of action. For many years, 
virtually all pharmaceutical companies had agrochemical divisions. Leads for pharmaceuticals and 
pesticides often overlap, in some cases leading to similar compounds used for human health and weed 
management purposes. Multiple activities of various herbicides/herbicide classes show potential 
pharmaceutical properties, both as therapeutic agents that act through human molecular target sites and 
those that act on infectious agents [38–40]. Moreover, good correlation between antimicrobial 
activities and herbicidal effects was found [15–17,32,41–46]. 
A primary series of the prepared compounds contains a basic scaffold of (tyrosine)kinase inhibitors 
[19,47,48]. The compounds were designed as potential antimycobacterial agents with innovative effect 
and they were evaluated on their activity against M. marinum, M. kansasii, M. smegmatis and M. 
avium subsp. paratuberculosis. As it is known that a number of antimicrobial compounds, similarly as 
some of quinoline analogues/bioisosteres, display also photosynthesis inhibiting activity (bond to PS II)  
[15–17,32,33,41–46], all the prepared compounds were evaluated in relation to inhibition of 
photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. Preliminary  
in vitro cytotoxicity screening of the most active derivatives was performed using the human 
monocytic leukemia THP-1 cell line. 
2. Results and Discussion 
2.1. Chemistry 
All the studied compounds were prepared according to Scheme 1 using a modified synthesis 
described by Lawrence et al. [49]. Reaction of 4,7-dichloroquinoline with appropriate aromatic amines 
in ethanol under reflux provided in quite good yields a series of twenty-five ring-substituted 
4-arylamino-7-chloroquinolinium chlorides 1–9c. 
The equivalent of HCl that was generated at reaction protonated the quinoline nitrogen that is much 
more basic than nitrogen in a spacer. pKa values predicted using the ACD/Percepta ver. 2012 program 
(Advanced Chemistry Development, Inc., Toronto, ON, Canada) for unsubstituted 7-chloro-4-
(phenylamino)quinoline were as follows: 5.1 ± 0.3 (quinoline nitrogen) and −0.8 ± 0.4 (spacer nitrogen). 
Predicted pKa values for 7-chloro-4-[(4-hydroxyphenyl)amino]quinoline were following:  
6.1 ± 0.5 (quinoline nitrogen) and −0.1 ± 0.5 (spacer nitrogen). 
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Scheme 1. Synthesis of 4-arylamino-7-chloroquinolinium chlorides 1–9c. 
R = H (1), OH (2a-c), OCH3 (3a-c), CH3 (4a-c), F (5a-c), Cl (6a-c), Br (7a-c), CF3 (8a-c), NO2 (9a-c)
N
R+
NH2
a
R
1-9c
N
H
Cl Cl
Cl HN
Cl
 
Reagents and Conditions: (a) ethanol, reflux. 
Lipophilicity of all compounds 1–9c was calculated as log P for the uncharged molecules using 
ACD/Percepta. The results are shown in Table 1. Compounds showed a wide range of lipophilicities, 
with log P values from 3.61 (2a, R = 2-OH) to 5.23 (8b, R = 3-CF3) within the series of 
ring-substituted 4-arylamino-7-chloroquinolines. For individual substituents in the aniline part of the 
discussed compounds also electronic Hammett’s σ parameters were predicted using the same software; 
they ranged from −0.38 (2a, R = 2-OH) to 0.78 (9c R = 4-NO2). 
2.2. Inhibition of Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
The activity of the evaluated ring-substituted 4-arylamino-7-chloroquinolinium chlorides related to 
inhibition of photosynthetic electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts 
was moderate or low relative to the standard, see Table 1. 
Table 1. Structure of ring-substituted 4-arylamino-7-chloroquinolinium chlorides 1–9c, 
calculated values of log P and electronic Hammett’s σ parameters, IC50 [μmol/L] values 
related to PET inhibition in spinach chloroplasts in comparison with 
3-(3,4-dichlorophenyl)-1,1-dimethylurea (DCMU) standard, in vitro antimycobacterial 
activity (MIC [μmol/L]) of compounds 1–9c compared to isoniazid (INH), pyrazinamide 
(PZA), rifampicin (RIF) and ciprofloxacin (CPX) standards and in vitro preliminary 
cytotoxicity screening (LD50) of selected compounds. 
Comp. R log P a σ a 
[μmol/L] 
PET 
IC50 
MIC 
LD50 MM MK MS MAP 
1 H 4.19 0 469 >879 >219 >879 >859 – 
2a 2-OH 3.61 −0.38 ND 834 208 104 813 – 
2b 3-OH 3.89 0.12 ND >834 >834 >834 >813 – 
2c 4-OH 3.71 −0.37 ND >834 >834 >834 >813 – 
3a 2-OCH3 4.66 −0.28 ND >797 >797 99.3 389 – 
3b 3-OCH3 4.66 0.12 238 >797 >797 >797 >778 – 
3c 4-OCH3 4.66 −0.27 ND >797 >797 >797 >778 – 
4a 2-CH3 4.45 −0.17 411 >839 >839 52.4 159 >20 
4b 3-CH3 4.76 −0.07 ND ND ND ND ND – 
4c 4-CH3 4.39 −0.17 ND ND ND ND ND – 
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Table 1. Cont. 
Comp. R log P a σ a 
[μmol/L] 
PET 
IC50 
MIC 
LD50 MM MK MS MAP 
5a 2-F 4.58 0.06 478 >828 828 103 >809 – 
5b 3-F 4.29 0.34 116 ND ND ND ND – 
5c 4-F 4.47 0.06 370 ND ND ND ND – 
6a 2-Cl 4.41 0.22 362 98.6 49.1 196 383 >20 
6b 3-Cl 4.50 0.37 55 ND ND ND ND – 
6c 4-Cl 4.18 0.23 211 ND ND ND ND – 
7a 2-Br 4.89 0.22 251 86.5 43.2 86.5 >675 >20 
7b 3-Br 5.14 0.39 89 ND ND ND ND – 
7c 4-Br 4.89 0.23 128 ND ND ND ND – 
8a 2-CF3 4.81 0.51 367 177 177 178 330 – 
8b 3-CF3 5.23 0.43 27 ND ND ND ND >20 
8c 4-CF3 5.05 0.51 33 ND ND ND ND >20 
9a 2-NO2 5.10 0.77 132 380 380 380 743 – 
9b 3-NO2 5.16 0.71 ND ND ND ND ND – 
9c 4-NO2 5.01 0.78 ND ND ND ND ND – 
DCMU – – – 1.9 – – – – – 
INH – – – – 467 29.2 117 >1823 – 
PZA – – – – – – – >2031 – 
RIF – – – – – – – >109 – 
CPX – – – – – – – 181 – 
a calculated for the uncharged molecules using ACD/Percepta (Advanced Chemistry Development, Inc., Toronto, 
ON, Canada, 2012); MM = M. marinum CAMP 5644, MK = M. kansasii DSM 44162, MM = M. smegmatis 
ATCC 700084 and clinical isolate MAP = M. avium subsp. paratuberculosis CIT03. ND = not determined 
due to precipitation during the experiment. 
Generally compounds showed poor aqueous solubility. PET inhibition of compounds 2a–3a, 3c, 4b, 
4c and 9b, 9c could not be determined due to precipitation of the compounds during the experiments. 
Compounds 8b (R = 3-CF3) and 8c (R = 4-CF3) expressed the highest PET-inhibiting activity (IC50 = 27 
and 33 µmol/L, respectively), while compound 5a (R = 2-F) and unsubstituted compound 1 showed 
the lowest PET-inhibiting activity (IC50 = 478 and 469 µmol/L, respectively). The PET-inhibiting 
activity was expressed by negative logarithm of IC50 value (compound concentration in mol/L causing 
50% inhibition of PET). Despite the relatively low inhibitory activity of the studied compounds, 
correlations between log(1/IC50 [mol/L]) and the lipophilicity of compounds expressed as log P or 
electronic properties of individual aniline substituents expressed as Hammett’s σ parameters were 
performed, see Figure 1. Based on the obtained results (see Table 1, Figure 1) it can be stated that 
substituents in  
meta- and para-position are preferred from the point of view of PET-inhibiting activity compared with 
ortho-position. 
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Figure 1. Relationships between PET inhibition log(1/IC50) [mol/L] in spinach 
chloroplasts and lipophilicity expressed as log P (Figure 1A) or N-substituent electronic 
Hammett’s σ parameters (Figure 1B) of selected studied compounds. 
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The biological activity is affected by lipophilicity. In general, the PET inhibition increases with 
increasing lipophilicity, see Figure 1A, where the dependence of log(1/IC50 [mol/L]) on log P is 
illustrated. However, compounds with R = 4-Cl (6c), 3-F (5b), 3-Cl (6b), 4-CF3 (8c) and 3-CF3 (8b) 
showed substantially higher inhibitory activity than other studied compounds with comparable 
lipophilicity. On the other hand, PET inhibition showed linear increase with electron-withdrawing 
substituent for ortho- as well as for meta- and para-substituted derivatives (Figure 1B) and the 
corresponding correlations could be expressed by following equations: 
ortho-substituted derivatives: log(1/IC50) = 3.371(±0.062) + 0.494(±0.168)σ 
r = 0.797, s = 0.131, F = 8.7, n = 7 
(1)
meta- and para-substituted derivatives: log(1/IC50) = 3.303(±0.089) + 2.343(±0.286)σ 
r = 0.945, s = 0.089, F = 67.0, n = 10 
(2)
The unsubstituted compound 1 is involved in both correlations. The good results of statistical 
analysis obtained for PET-inhibiting activity of meta- and para-substituted compounds [Equation (2)] 
indicate considerable effect of electronic properties of individual aniline substituents on biological 
activity. On the other hand, the activity of less active ortho-substituted derivatives was characterized 
by considerable variance what resulted in worse results of statistical analysis [Equation (1)]. The lower 
activity of ortho-substituted compounds could be connected with intramolecular interactions of R 
substituent with NH group resulting in reduced interaction of these compounds with photosynthetic 
proteins embedded in thylakoid membranes. 
The linear course of the dependence of log(1/IC50) on σ indicates that for the PET-inhibiting 
activity not only sufficient lipophilicity (enabling easier penetration of the compounds into the lipids 
of photosynthetic membranes) but also sufficient electronegativity of the R substituent (affecting 
interactions with proteins in photosynthetic apparatus) is necessary. Compounds 8b (R = 3-CF3,  
IC50 = 27 μmol/L) and 8c (R = 4-CF3, IC50 = 33 μmol/L) were the most active compounds from the 
series, and this result can indicate that PET inhibition can be associated with favourable interaction of 
the trifluoromethyl moiety with photosynthetic proteins. A strong dependence of PET-inhibiting 
activity on σ was also found for 2-benzylsulphanylbenzimidazoles [50]. 
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For specification of the site of action of certain PS II inhibitor an artificial electron donor 
1,5-diphenylcarbazide (DPC) acting in Z•/D• intermediate [51] that is situated on the donor side of PS II 
can be used. If addition of DPC results in complete PET restoration in chloroplasts activity of which was 
suppressed by an inhibitor, the site of inhibitory action of this inhibitor is situated on the donor side of PS II in 
the section between oxygen evolving complex and Z•/D• intermediate. On the other hand, if PET was 
interrupted on the acceptor side of PS II, despite supply of electrons by DPC, the electron flow cannot 
be restored. Because addition of DPC to chloroplasts activity of which was inhibited by the studied 
compounds (up to 30% of the control) restored PET only partially (at the most 74%–85% of the 
control) it can be concluded, that the sites of action of these inhibitors are situated on both sides of PS 
II. That means that the studied compounds act besides of donor side of PS II also on its acceptor side, 
namely in the section between the core of PS II (P680) and the secondary plastoquinone acceptor QB. 
The site of action situated on the donor side of PS II was found also for 2-alkylthio-6-R-benzothiazoles 
(R = 6-formamido-, 6-acetamido-, and 6-benzoylamino-) [52], anilides of 2-alkylpyridine-4-carboxylic 
acids acting in intermediates Z•/D• [53], 5-bromo-N-phenylbenzamides [54] and 2-alkylsulphanyl-4-
pyridinecarbothioamides acting in the D• intermediate [55], while anilides of 2-alkyl-substituted 
4-pyridinecarboxylic acid with hydroxy substituent in the anilide part of the compound [53] as well as 
some anilides of N-benzylpyrazine-2-carboxamides [56] inhibited PET also between P680 and 
plastoquinone QB occurring on the acceptor side of PS II. 
Figure 2. Fluorescence emission spectra of chlorophyll a in untreated spinach chloroplasts 
in presence of compound 8b: 0, 0.06, 0.12, 0.24, 0.48 and 0.72 mmol/L (curves from top to 
bottom; λex = 436 nm). Chlorophyll concentration in chloroplast suspension was constant, 
10 mg/L. 
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The effects of the studied compounds on the photosynthetic apparatus of spinach chloroplasts were 
investigated by studying chlorophyll a (Chla) fluorescence using chloroplast suspension with constant 
chlorophyll concentration 10 mg/L. The fluorescence emission band at λ = 686 nm belongs to the 
pigment-protein complexes in PS II [57] and the perturbation of chlorophyll a-protein complexes in the 
thylakoid membrane caused by PET inhibitors is reflected in fluorescence decrease. As in the presence 
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of studied compounds the intensity of this emission band showed gradual decrease with increasing 
concentration of 8b, PS II could be suggested as the site of action of this compound, see Figure 2, and 
similar effect was observed also with other studied compounds. A decline of Chla fluorescence at  
λ = 686 nm was observed previously in the presence of substituted carboxamides/anilides 
[41,43,45,46,53–56,58], quinoline derivatives [33] and N-substituted 2-aminobenzothiazoles [44,52]. 
2.3. In Vitro Antimycobacterial Evaluation 
The evaluation of the in vitro antimycobacterial activity of all the compounds was performed 
against Mycobacterium marinum, M. kansasii and M. smegmatis as model species for screening of 
prospective antimycobacterial drugs to control mycobacterial diseases. A clinical isolate of M. avium 
subsp. paratuberculosis, which causes gastrointestinal diseases and is resistant to standard 
antituberculotics [59], was also involved in the screening. Isoniazid was chosen as a standard for all 
tested strains, nevertheless as it was observed that isoniazid is inactive against the clinical isolate, 
pyrazinamide  
and rifampicin (as first-line antituberculotic drugs) and ciprofloxacin (as an alternative 
antituberculotic/antimycobacterial drug) were also used as standards for estimation of the resistance of 
this clinical isolate. Most of compounds showed only moderate or no activity, see Table 1, only 
ortho-substituted derivatives demonstrated some antimycobacterial effect, the rest of compounds 
displayed problematic aqueous solubility. 4-[(2-Bromophenyl)amino]-7-chloroquinolinium chloride 
(7a) showed the highest biological activity against M. marinum and M. kansasii, and it was also active 
against M. smegmatis. 7-Chloro-4-[(2-methylphenyl)amino] quinolinium chloride (4a) demonstrated 
the highest biological activity against M. smegmatis and M. avium subsp. paratuberculosis. Both 
compounds showed comparable or higher activity than the standard isoniazid. Compound 4a  
showed even higher activity than the standard ciprofloxacin in case of the clinical isolate M. avium 
subsp. paratuberculosis. 
Although the number of compounds demonstrating antimycobacterial activity is limited, 
correlations between log(1/MIC [mol/L]) and electronic properties of individual substituents on aniline 
ring expressed as Hammett’s σ parameters or the lipophilicity of compounds expressed as log P can be 
found, see Figure 3. According to the results (see Table 1), it can be generally concluded that activity 
is significantly influenced by electronic properties and lipophilicity. The optimal range of lipophilicity, 
log P = 4.41–4.89 (Figures 3A,B), facilitates permeation through hydrophobic mycobacterial wall, 
while electronic properties can influence the potential of binding of the arylamino quinoline scaffold to 
possible binding sites [10]. The dependencies between activity and electronic Hammett’s σ parameters 
for all the compounds were observed as bilinear with the σ optimum ca. 0.22 for M. marinum and 
M. kansasii, and with the σ optimum ca. −0.17 for M. smegmatis and M. avium subsp. 
paratuberculosis, see Figure 3C,D. This fact may correspond with different site of action/binding site 
in M. marinum/M. kansasii and in M. smegmatis/M. avium subsp. paratuberculosis, because 
ortho-substitution influences electron distribution in the whole aromatic conjugated system. Moreover, 
the antimycobacterial activity of these ortho-derivatives is evidently related to twist conformation of 
the whole arylaminoquinoline scaffold, because the proximity of the ortho-substituent to the quinoline 
nucleus on the aniline ring led to the twist of the aniline ring plain towards the quinoline nucleus, 
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i.e. the whole cyclic system is not planar. Similar SAR non-planar requirements can be also found, for 
example, for clonidine, phenamates, phenacs, etc. [9]. 
Figure 3. Dependences of in vitro antimycobacterial activity against M. marinum 
log(1/MIC [mol/L]) on lipophilicity (Figure 3A) and on N-substituent electronic Hammett’s 
σ parameters (Figure 3C) or in vitro activity against M. smegmatis log(1/MIC [mol/L]) on 
lipophilicity (Figure 3B) and on N-substituent electronic Hammett’s σ parameters (Figure 
3D) of studied ring-substituted 4-arylamino-7-chloroquinolinium chlorides. 
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2.4. In Vitro Cytotoxicity Assay 
The preliminary in vitro screening of cytotoxicity of the selected most effective compounds 4a, 6a, 
7a, 8b and 8c was performed using the human monocytic leukemia THP-1 cell line. The cytotoxicity 
was evaluated as the LD50 value (LD50 - lethal dose to 50% of the cell population - see Table 1). In the 
past several works were published, where the toxicity of tested compounds (including antibacterial 
agents [16,44–46]) was assessed on THP-1 cells. Due to low aqueous solubility of the studied 
compounds their utilizable concentration range in the cytotoxicity test was significantly limited. The 
highest dose of all tested compounds in the medium (20 μmol/L) did not lead to significant lethal 
effect on THP-1 cells. All the evaluated compounds demonstrated low toxicity in the highest available 
concentration against the human monocytic leukemia THP-1 cell line with LD50 > 20 μmol/L. As LD50 
values of oxaliplatin and camptothecin assessed in this line formerly were by one or two orders lower 
(1.7 ± 0.64 μmol/L and 0.16 ± 0.07 μmol/L, respectively), the discussed substances can be considered 
as non-toxic agents for subsequent design of novel antimycobacterial agents. 
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3. Experimental 
3.1. General 
All reagents were purchased from Sigma-Aldrich (Munich, Germany). The plates were illuminated 
under UV (254 nm) and evaluated in iodine vapour. The melting points were determined on Kofler  
hot-plate apparatus HMK (Franz Kustner Nacht KG, Dresden, Germany) and are uncorrected. Infrared 
(IR) spectra were recorded on a Smart MIRacle™ ATR ZnSe for Nicolet™ Impact 410 FT-IR 
spectrometer (Thermo Electron Corporation, West Palm Beach, FL, USA). The spectra were obtained 
by accumulation of 256 scans with 2 cm−1 resolution in the region of 4000–600 cm−1. All 1H- and 
13C-NMR spectra were recorded on a Bruker Avance III 400 MHz FT-NMR spectrometer (400 MHz 
for 1H and 100 MHz for 13C, Bruker Comp., Karlsruhe, Germany). Chemicals shifts (δ) are reported in 
ppm. Proton chemical shifts in DMSO-d6 are related to the middle of the solvent multiplet (δ = 2.50). 
13C-NMR spectra were measured using APT pulse sequences. Carbon chemical shifts are referenced to 
the middle of the solvent multiplet (δ = 39.5 in DMSO-d6). Mass spectra were measured using a LTQ 
Orbitrap Hybrid Mass Spectrometer (Thermo Electron Corporation, West Palm Beach, FL, USA) with 
direct injection into an APCI source (400 °C) in the positive mode. 
HPLC monitoring analyses were performed on Thermo Scientific UHPLC Accela 1250 system 
connected to a Thermo Scientific TSQ Quantum Access MAX Triple Quadrupole Instrument (Thermo, 
San Jose, CA, USA) equipped with heated electrospray ionization (HESI-II) probe. A Thermo 
Scientific Hypersil C18 (2.1 mm × 50 mm, 1.9 μm) column was used at a constant flow rate of 300 μL/min. 
Mobile phase consisted of water containing 0.1% formic acid (v/v) (solvent A) and acetonitrile 
containing 0.1% formic acid (solvent B). The gradient used was: 0–10 min from 20 to 95% B; 10-11 min 
from 95 to 20% B and 11–11.5 min held at 20% B in order for the column to re-equilibrate before the 
next injection. The full loop injection volume was set at 10 μL. The heated electrospray ionization was 
operated in the positive-ion mode under the following conditions: Capillary Temperature: 325.0 °C; 
Vaporizer Temperature 300.0 °C; Sheath Gas Pressure 35.0 psi; Auxiliary (drying) gas 10 a.u.; Spray 
Voltage 3300 V. Formic acid was purchased from Sigma-Aldrich (Munich, Germany). All solvents 
were residual analysis purity (Chromservis, Prague, Czech Republic). 
3.2. Synthesis 
General Procedure for synthesis of 4-arylamino-7-chloroquinolinium chlorides 1–9c 
The appropriate aromatic amine (5 mmol) was added at once to solution of 4,7-dichloroquinoline  
(5 mmol) in 40 mL of 96% ethanol at 25 °C. The reaction was heated and kept under reflux until HPLC 
analysis revealed complete disappearance of the starting materials. Reaction media was cooled to 
ambient temperature and formed precipitate was separated by filtration and triturated with 40 mL of 
fresh hot 96% ethanol. Suspension was cooled again, filtered and solid was successively washed with 96% 
ethanol and dichloromethane. Yellow to orange product was dried in desiccator under reduced pressure. 
7-Chloro-4-(phenylamino)quinolinium chloride (1). Yield 87%; Mp. 274–276 °C; IR (Zn/Se ATR, 
cm−1): 2638w, 1609w, 1576w, 1533w, 1448w, 1361w, 1205w, 894w, 804m, 739m, 687s; 1H-NMR 
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(DMSO-d6), δ: 11.28 (br. s, 1H), 8.93 (d, J = 9.0 Hz, 1H), 8.51 (d, J = 7.0 Hz, 1H), 8.20 (d, J = 2.0 Hz, 
1H), 7.86 (dd, J = 9.0 Hz, J = 2.3 Hz, 1H), 7.60–7.56 (m, 2H), 7.51–7.48 (m, 2H), 7.46-7.42 (m, 1H), 
6.77 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 154.89, 143.32, 139.08, 138.36, 136.97, 
129.97, 127.62, 127.32, 126.25, 125.47, 119.17, 115.94, 100.22; HR-MS: for C15H12ClN2+ [M+H]+ 
calculated 255.0684 m/z, found 255.0680 m/z. 
7-Chloro-4-[(2-hydroxyphenyl)amino]quinolinium chloride (2a) [60]. Yield 90%; Mp. 269–270 °C; IR 
(Zn/Se ATR, cm−1): 3156w, 2774w, 1609w, 1585m, 1544m, 1442s, 1367m, 1233w, 1202m, 1157w, 
882w, 844w, 797m, 741s, 655s; 1H-NMR (DMSO-d6), δ: 10.99 (br. s, 1H), 10.32 (br. s, 1H), 8.91 (d,  
J = 9.0 Hz, 1H), 8.48 (d, J = 7.0 Hz, 1H), 8.19 (s, 1H), 7.8 (d, J = 8.8 Hz, 1H) 7.28–7.31 (m, 2H), 7.17 
(d, J = 8.0 Hz, 1H), 6.94 (t, J = 7.4 Hz, 1H), 6.30 (d, J = 6.8 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 
155.49, 153.01, 142.80, 139.06, 138.37, 129.65, 128.31, 127.29, 126.55, 123.51, 119.98, 119.23, 
117.40, 115.78, 101.16; HR-MS: for C15H12ClN2O+ [M+H]+calculated 271.0633 m/z, found 271.0637 m/z. 
7-Chloro-4-[(3-hydroxyphenyl)amino]quinolinium chloride (2b) [49]. Yield 48%; Mp. 298–299 °C; 
IR (Zn/Se ATR, cm−1): 3160w, 2805w, 1610m, 1577s, 1539m, 1497w, 1448s, 1409w, 1373w, 1297w, 
1210m, 1160w, 1095w, 876w, 848w, 806m, 770m, 669s; 1H-NMR (DMSO-d6), δ: 11.15 (s, 1H), 10.05 
(br. s, 1H), 8.88 (d, J = 9.3 Hz, 1H), 8.51 (d, J = 7.0 Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 7.82 (dd, J = 
9.0 Hz, J = 1.8 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 6.89–6.79 (m, 4H); 13C-NMR APT (DMSO-d6), δ: 
158.78, 154.86, 143.19, 139.04, 138.34, 137.84, 130.67, 127.25, 126.25, 119.11, 115.89, 115.62, 
114.79, 112.25, 100.41; HR-MS: for C15H12ClN2O+ [M+H]+ calculated 271.0633 m/z, found 271.0634 m/z. 
7-Chloro-4-[(4-hydroxyphenyl)amino]quinolinium chloride (2c) [61]. Yield 99%; Mp. 303–305 °C; IR 
(Zn/Se ATR, cm−1): 3007w, 2768w, 1607m, 1586m, 1536m, 1506s, 1438m, 1358w, 1220m, 1161w, 
1123w, 1096w, 893w, 847w, 809s, 784w, 727m, 658m; 1H-NMR (DMSO-d6), δ: 11.03 (br. s, 1H), 
9.97 (br. s, 1H), 8.84 (d, J = 9.3 Hz, 1H), 8.44 (d, J = 7.0 Hz, 1H), 8.14 (br. s, 1H), 7.78 (br. s, 1H), 
7.24 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), 
δ: 157.04, 155.21, 143.12, 139.19, 138.13, 127.75, 127.11, 126.09, 121.68, 119.27, 116.44, 115.67, 
99.93; HR-MS: for C15H12ClN2O+ [M+H]+ calculated 271.0633 m/z, found 271.0636 m/z. 
7-Chloro-4-[(2-methoxyphenyl)amino]quinolinium chloride (3a). Yield 31%; Mp. 230–231 °C; IR 
(Zn/Se ATR, cm−1): 2679w, 1611m, 1590m, 1540m, 1494w, 1452m, 1371w, 1279w, 1259s, 1214m, 
1177w, 1114w, 1023m, 936w, 909w, 864w, 810s, 780s, 759m, 694m, 660m; 1H-NMR (DMSO-d6), δ: 
11.16 (br. s, 1H), 8.98 (d, J = 9.0 Hz, 1H), 8.47 (d, J = 6.8, 1H), 8.23 (s, 1H), 7.80 (d, J = 9.0 Hz, 1H), 
7.47–7.39 (m, 2H), 7.26 (d, J = 8.3 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 6.27 (d, J = 7.0 Hz, 1H), 3.75 (s, 
3H); 13C-NMR APT (DMSO-d6), δ: 155.24, 154.23, 142.66, 138.88, 138.18, 129.70, 128.10, 127.17, 
126.33, 124.64, 121.18, 119.06, 115.47, 112.87, 100.82, 55.72; HR-MS: for C16H14ClN2O+ [M+H]+ 
calculated 285.0789 m/z, found 285.0787 m/z. 
7-Chloro-4-[(3-methoxyphenyl)amino]quinolinium chloride (3b). Yield 54%; Mp. 249–250 °C; IR 
(Zn/Se ATR, cm−1): 2647w, 1606m, 1584w, 1536w, 1501, 1441m, 1231m, 1208w, 1160w, 1096w, 
1031m, 893m, 844w, 806s, 778s, 753w, 661s; 1H-NMR (DMSO-d6), δ: 11.34 (br. s, 1H), 8.98 (d,  
J = 9.0 Hz, 1H), 8.50 (d, J = 7.0 Hz, 1H), 8.20 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 9.0 Hz, J = 2.0 Hz, 
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1H), 7.45 (t, J = 8.0 Hz, 1 H), 7.06–7.04 (m, 2H), 6.99–6.96 (m, 1H), 6.83 (d, J = 7.0 Hz, 1H), 3.76  
(s, 3H); 13C-NMR APT (DMSO-d6), δ: 160.28, 154.79, 143.16, 139.00, 138.28, 138.13, 130.67, 
127.19, 126.41, 119.02, 117.26, 115.92, 113.09, 111.08, 100.49, 55.41; HR-MS: for C16H14ClN2O+ 
[M+H]+ calculated 285.0789 m/z, found 285.0788 m/z. 
7-Chloro-4-[(4-methoxyphenyl)amino]quinolinium chloride (3c) [62]. Yield 44%; Mp. 286–287 °C; 
IR (Zn/Se ATR, cm−1): 2647w, 1606s, 1584m, 1536s, 1501s, 1442s, 1362w, 1231m, 1208m, 1160m, 
1096w, 1031m, 893m, 845w, 806s, 778s, 753w; 1H-NMR (DMSO-d6), δ: 11.26 (s, 1H), 8.94 (d,  
J = 9.3 Hz, 1H), 8.46 (d, J = 7.0 Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 9.0 Hz, J = 2.3 Hz, 
1H), 7.40–7.36 (m, 2H), 7.11–7.07 (m, 2H), 6.62 (d, J = 7.0 Hz, 1H), 3.80 (s, 3H); 13C-NMR APT 
(DMSO-d6), δ: 158.42, 155.24, 142.94, 138.96, 138.23, 129.42, 127.11 (2C), 126.31, 118.99, 115.70, 
115.07, 99.93, 55.46; HR-MS: for C16H14ClN2O+ [M+H]+ calculated 285.0789 m/z, found 285.0788 m/z. 
7-Chloro-4-[(2-methylphenyl)amino]quinolinium chloride (4a). Yield 93%; Mp. 247–248 °C; IR 
(Zn/Se ATR, cm−1): 2583w, 1605m, 1540m, 1488w, 1443w, 1359m, 1200m, 882w, 815s, 761w, 739s, 
692s, 659m; 1H-NMR (DMSO-d6), δ: 11.28 (br. s, 1H), 9.01 (d, J = 9.3 Hz, 1H), 8.47 (d, J = 7.0 Hz, 
1H), 8.22 (d, J = 1.8 Hz, 1H), 7.85 (dd, J = 9.2 Hz, J = 1.9 Hz, 1H), 7.48–7.46 (m, 1H), 7.42–7.35 (m, 
3H), 6.21 (d, J = 7.0 Hz, 1H); 2.21 (s, 3H); 13C-NMR APT (DMSO-d6), δ: 155.50, 143.20, 139.00, 
138.34, 135.34, 135.23, 131.60, 128.66, 127.63, 127.55, 127.28, 126.36, 119.13, 115.54, 99.93, 17.34; 
HR-MS: for C16H14ClN2+ [M+H]+ calculated 269.0840 m/z, found 269.0841 m/z. 
7-Chloro-4-[(3-methylphenyl)amino]quinolinium chloride (4b). Yield 50%; Mp. 279–281 °C; IR 
(Zn/Se ATR, cm−1): 2646w, 1610m, 1578m, 1535m, 1446m, 1361w, 1326w, 1235w, 1208w, 1158w, 
1095w, 895s, 850w, 802w, 768s, 685s; 1H-NMR (DMSO-d6), δ: 11.21 (br. s, 1H), 8.91 (d, J = 9.0 Hz, 
1H), 8.5 (d, J = 7.0 Hz, 1H), 8.20 (d, J = 2.0 Hz, 1H), 7.85 (dd, J = 9.0 Hz, J = 2.0 Hz, 1H),  
7.47–7.43 (m, 1H), 7.30–7.24 (m, 3H), 6.77 (d, J = 7.0 Hz, 1H), 2.38 (s, 3H); 13C-NMR APT (DMSO-
d6), δ: 154.88, 143.27, 139.60, 139.08, 138.34, 136.86, 129.78, 128.30, 127.30, 126.21, 125.84, 
122.48, 119.18, 115.89, 100.28, 20.93; HR-MS: for C16H14ClN2+ [M+H]+ calculated 269.0840 m/z, 
found 269.0848 m/z. 
7-Chloro-4-[(4-methylphenyl)amino]quinolinium chloride (4c). Yield 90%; Mp. 297–298 °C; IR 
(Zn/Se ATR, cm−1): 2644w, 1605m, 1585m, 1536m, 1508m, 1444s, 1361w, 1325w, 1233w, 1211m, 
1164w, 1098w, 896m, 864w, 806s, 778s, 676s; 1H-NMR (DMSO-d6), δ: 11.12 (s, 1H), 8.85 (d,  
J = 9.0 Hz, 1H), 8.49 (d, J = 7.0 Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H), 7.87 (dd, J = 9.0 Hz, J = 2.0 Hz, 
1H), 7.40–7.35 (m, 4H), 6.72 (d, J = 7.0 Hz, 1H), 2.38 (s, 3H); 13C-NMR APT (DMSO-d6), δ: 155.03, 
143.29, 139.07, 138.34, 137.24, 134.28, 130.45, 127.30, 126.07, 125.42, 119.23, 115.84, 100.14, 
20.71; HR-MS: for C16H14ClN2+ [M+H]+ calculated 269.0840 m/z, found 269.0838 m/z. 
7-Chloro-4-[(2-fluorophenyl)amino]quinolinium chloride (5a). Yield 99%; Mp. 279–280 °C; IR 
(Zn/Se ATR, cm−1): 2580w, 1587m, 1540m, 1496m, 1145m, 1362w, 1239w, 1205m, 895m, 807s, 
747s, 678s; 1H-NMR (DMSO-d6), δ: 11.32 (br. s, 1H), 8.98 (d, J = 9.2 Hz, 1H), 8.58 (d, J = 6.6 Hz, 
1H), 8.25 (d, J = 2.1 Hz, 1H), 7.89 (dd, J = 8.1 Hz, J = 2.0 Hz, 1H), 7.62–7.48 (m, 3H), 7.44–7.39 (m, 
1H), 6.49 (dd, J = 7.1 Hz, J = 2.6 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 156.82 (d, 1JCF = 249.5 Hz), 
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155.19, 143.59, 138.96, 138.50, 130.18 (d, 3JCF = 8.0 Hz), 128.96, 127.65, 126.29, 125.85, 124.29 (d, 
2JCF = 13.1 Hz), 119.30, 117.12 (d, 2JCF = 19.1 Hz), 115.73, 100.78; HR-MS: for C15H11ClFN2+ 
[M+H]+ calculated 273.0589 m/z, found 273.0591 m/z. 
7-Chloro-4-[(3-fluorophenyl)amino]quinolinium chloride (5b). Yield 48%; Mp. 241–242 °C; IR 
(Zn/Se ATR, cm−1): 2587w, 1580m, 1535w, 1482m, 1447m, 1404w, 1366w, 1231w, 1205w, 1142w, 
879m, 825w, 778s, 720m, 681s; 1H-NMR (DMSO-d6), δ: 11.46 (br. s, 1H), 9.00 (d, J = 9.3 Hz, 1H), 
8.55 (d, J = 7.0 Hz, 1H), 8.21 (d, J = 2.3 Hz, 1H), 7.81 (dd, J = 9.2 Hz, J = 2.1 Hz, 1H), 7.61–7.55 
(m, 1H), 7.43–7.38 (m, 2H), 7.25 (td, J = 8.4 Hz, J = 2.3 Hz, 1H), 6.90 (d, J = 6.8 Hz, 1H); 13C-NMR 
APT (DMSO-d6), δ: 162.50 (d, 1JCF = 245.5 Hz), 154.59, 143.45, 139.01, 138.85 (d, 3JCF = 10.1 Hz), 
138.39, 131.52 (d, 3JCF = 9.1 Hz), 127.37, 126.49, 121.29 (d, 4JCF = 3.0 Hz), 119.09, 116.08, 114.17 (d, 
2JCF = 20.1 Hz), 112.48 (d, 2JCF = 20.1 Hz), 100.70; HR-MS: for C15H11ClFN2+ [M+H]+ calculated 
273.0589 m/z, found 273.0593 m/z. 
7-Chloro-4-[(4-fluorophenyl)amino]quinolinium chloride (5c). Yield 54%; Mp. 304–305 °C; IR 
(Zn/Se ATR, cm−1): 2646w, 1606m, 1579w, 1535w, 1498m, 1445m, 1361w, 1205s, 1093w, 894w, 
847m, 824s, 804s, 782s, 757m, 681s; 1H-NMR (DMSO-d6), δ: 11.18 (br. s, 1H), 8.86 (d, J = 9.0 Hz, 
1H), 8.53 (d, J = 6.8 Hz, 1H), 8.17 (d, J = 2.3 Hz, 1H), 7.89 (dd, J = 9.0 Hz, J = 2.3 Hz, 1H), 7.54 (dd,  
J = 9.0 Hz, J = 5.0 Hz, 2H), 7.45–7.41 (m, 2H), 6.72 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), 
δ: 160.93 (d, 1JCF = 244.5 Hz), 155.19, 143.48, 139.05, 138.42, 133.27, 127.97 (d, 3JCF = 9.1 Hz), 127.41, 
126.11, 119.27, 116.89 (d, 2JCF = 22.1 Hz), 115.86, 100.23; HR-MS: for C15H11ClFN2+ [M+H]+ 
calculated 273.0589 m/z, found 273.0594 m/z. 
7-Chloro-4-[(2-chlororophenyl)amino]quinolinium chloride (6a). Yield 99%; Mp. 241–243 °C; IR 
(Zn/Se ATR, cm−1): 2733w, 1606m, 1578w, 1535s, 1474w, 1439m, 1358w, 1205w, 1040w, 882w, 
805s, 757s; 1H-NMR APT (DMSO-d6), δ: 11.52 (br. s, 1H), 9.02–8.99 (m, 1H), 8.55 (m, 1H), 8.27 (br. 
s, 1H), 7.87 (d, J = 9.0 Hz, 1H), 7.73 (d, J = 7.0 Hz, 1H), 7.63–7.52 (m, 3H), 6.28–6.24 (m, 1H);  
13C-NMR (DMSO-d6), δ: 155.48, 143.60, 139.17, 138.72, 134.18, 131.30, 130.99, 130.48, 130.04, 
129.26, 127.81, 126.52, 119.45, 115.73, 100.90; HR-MS: for C15H11Cl2N2+ [M+H]+ calculated 
289.0294 m/z, found 289.0297 m/z. 
7-Chloro-4-[(3-chlororophenyl)amino]quinolinium chloride (6b). Yield 50%; Mp. 261–262 °C; IR 
(Zn/Se ATR, cm−1): 2645 w, 1611w, 1579s, 1530m, 1445s, 1404w, 1356m, 1330w, 1239w, 1207m, 
1164w, 1089m, 881m, 825m, 796s, 771s, 720s, 696s, 673s; 1H-NMR (DMSO-d6), δ: 11.38 (br. s, 1H), 
8.95 (d, J = 9.0 Hz, 1H), 8.56 (d, J = 7.0 Hz, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.87 (dd, J = 9.0 Hz,  
J = 2.0 Hz, 1H), 7.63–7.59 (m, 2H), 7.51–7.48 (m, 2H), 6.88 (d, J = 7.0 Hz, 1H); 13C-NMR APT 
(DMSO-d6), δ: 154.68, 143.60, 139.08, 138.69, 138.45, 133.96, 131.52, 127.48, 127.33, 126.38, 
125.20, 124.00, 119.23, 116.13, 100.73; HR-MS: for C15H11Cl2N2+ [M+H]+ calculated 289.0294 m/z, 
found 289.0296 m/z. 
7-Chloro-4-[(4-chlororophenyl)amino]quinolinium chloride (6c) [63]. Yield 51%; Mp. 292–293 °C; 
IR (Zn/Se ATR, cm−1): 2645w, 1608m, 1581w, 1482w, 1441m, 1360w, 1232w, 1207w, 1084w, 894m, 
846w, 806s, 772m, 670s; 1H-NMR (DMSO-d6), δ: 11.25 (br. s, 1H), 8.89 (d, J = 9.0 Hz, 1H), 8.55 (d, 
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J = 6.8 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.88 (dd, J = 9.0 Hz, J = 2.0 Hz, 1H), 7.65–7.62 (m, 2H), 
7.55–7.52 (m, 2H), 6.84 (d, J = 7.0 Hz, 1 H); 13C-NMR APT (DMSO-d6), δ: 154.79, 143.57, 139.11, 
138.45, 136.05, 131.65, 129.94, 127.46, 127.25, 126.23, 119.29, 116.08, 100.51; HR-MS: for 
C15H11Cl2N2+ [M+H]+ calculated 289.0294 m/z, found 289.0296 m/z. 
4-[(2-Bromophenyl)amino]-7-chloroquinolinium chloride (7a). Yield 83%; Mp. 234–235 °C; IR 
(Zn/Se ATR, cm−1): 2730w, 1606m, 1579m, 1535s, 1470w, 1440m, 1360w, 1231w, 1209m, 1156w, 
1034w, 883w, 806s, 756s, 653s; 1H-NMR (DMSO-d6), δ: 11.52 (br. s, 1H), 9.00 (d, J = 9.3 Hz, 1H), 
8.55 (d, J = 7.0 Hz, 1H), 8.27 (d, J = 2.0 Hz, 1H), 7.90–7.86 (m, 2H), 7.61–7.60 (m, 2H), 7.46 (ddd,  
J = 8.2 Hz, J = 5.3 Hz, J = 3.9 Hz, 1H), 6.23 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 
155.30, 143.32, 138.95, 138.54, 135.49, 133.95, 130.57, 130.01, 129.69, 127.63, 126.27, 121.84, 
119.24, 115.46, 100.67; HR-MS: for C15H11BrClN2+ [M+H]+ calculated 332.9789 m/z, found 332.9792 
m/z. 
4-[(3-Bromophenyl)amino]-7-chloroquinolinium chloride (7b). Yield 97%; Mp. 294–295 °C; IR 
(Zn/Se ATR, cm−1): 2731w, 1609m, 1574m, 1528m, 1446m, 1407w, 1360w, 1323w, 1231w, 1207w, 
1158w, 1096w, 1031m, 893m, 844w, 806s, 778s, 753w, 661s; 1H-NMR (DMSO-d6), δ: 11.37 (br. s, 
1H), 8.93 (d, J = 9.0 Hz, 1H), 8.57 (d, J = 7.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.87 (dd, J = 9.0 Hz,  
J = 2.0 Hz, 1H), 7.76–7.75 (m, 1H), 7.64–7.61 (m, 1H), 7.55–7.52 (m, 2H), 6.88 (d, J = 7.0 Hz, 1H); 
13C-NMR APT (DMSO-d6), δ: 154.88, 143.61, 139.08, 138.80, 138.45, 131.76, 130.23, 128.01, 
127.48, 126.34, 124.37, 122.27, 119.23, 116.12, 100.71; HR-MS: for C15H11BrClN2+ [M+H]+ 
calculated 332.9789 m/z, found 332.9793 m/z. 
4-[(4-Bromophenyl)amino]-7-chloroquinolinium chloride (7c). Yield 99%; Mp. 293–294 °C; IR 
(Zn/Se ATR, cm−1): 2699w, 1606m, 1578w, 1529m, 1480w, 1440m, 1360w, 1232w, 1208w, 1063w, 
894m, 806s, 769m, 665m; 1H-NMR (DMSO-d6), δ: 11.18 (br. s, 1H), 8.85 (d, J = 9.3 Hz, 1H), 8.55 (d, 
J = 8.0 Hz, 1 H), 8.17 (s, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 
6.86 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 154.68, 143.69, 139.14, 138.46, 136.49, 
132.89, 128.08, 127.49, 126.15, 120.01, 119.36, 116.11, 100.57; HR-MS: for C15H11BrClN2+ [M+H]+ 
calculated 332.9789 m/z, found 332.9794 m/z. 
7-Chloro-4-[(2-trifluoromethylphenyl)amino]quinolinium chloride (8a). Yield 59%; Mp. 217–218 °C; 
IR (Zn/Se ATR, cm−1): 2382w, 1584m, 1538m, 1494w, 1441m, 1420w, 1353w, 1309s, 1235w, 1206m, 
1168m, 1124m, 1090m, 1000w, 954w, 910w, 864m, 812s, 772m, 730w; 1H-NMR (DMSO-d6), δ: 
11.44 (br. s, 1H), 8.98 (d, J = 9.0 Hz, 1H), 8.53 (d, J = 6.8 Hz, 1H), 8.27–8.26 (m, 1H), 7.85 (dd,  
J = 9.0 Hz, J = 2.0 Hz, 1H), 7.78–7.70 (m, 2H), 7.55–7.52 (m, 2H), 6.16 (d, J = 7.0 Hz, 1H); 
13C-NMR APT (DMSO-d6), δ: 156.54, 147.49, 139.37, 137.50, 134.97, 134.80 (q, 3JCF = 1.5 Hz), 
129.83, 127.83 (q, 3JCF = 4.4 Hz), 127.74, 127.19 (q, 2JCF = 30.1 Hz), 126.42, 126.12, 125.88, 123.17 
(q, 1JCF = 273.6 Hz), 115.43, 100.92; HR-MS: for C16H11ClF3N2+ [M+H]+ calculated 323.0557 m/z, found 
323.0561 m/z. 
7-Chloro-4-[(3-trifluoromethylphenyl)amino]quinolinium chloride (8b). Yield 49%; Mp. 291–292 °C; 
IR (Zn/Se ATR, cm−1): 2744w, 1608m, 1580m, 1535m, 1452m, 1411w, 1371w, 1324s, 1267w, 1208w, 
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1168m, 1104m, 1062m, 963w, 890s, 808s, 772m, 697m, 667s; 1H-NMR (DMSO-d6), δ: 11.42 (br. s, 
1H), 8.93 (d, J = 9.0 Hz, 1H), 8.59 (d, J = 7.0 Hz, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.92–7.89 (m, 2H), 
7.87–7.77 (m, 3H), 6.90 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 154.70, 143.84, 139.17, 
138.50, 138.15, 131.21, 130.56 (q, 2JCF = 32.2 Hz), 129.27, 127.58, 126.31, 123.90 (q, 3JCF = 4.0 Hz), 
123.76 (q, 1JCF = 273.7 Hz), 122.03 (q, 3JCF = 4.0 Hz), 119.35, 116.25, 100.69; HR-MS: for 
C16H11ClF3N2+ [M+H]+ calculated 323.0557 m/z, found 323.0560 m/z. 
7-Chloro-4-[(4-trifluoromethylphenyl)amino]quinolinium chloride (8c). Yield 99%; Mp. 301–302 °C; 
IR (Zn/Se ATR, cm−1): 2646w, 1582m, 1528m, 1442m, 1411w, 1319s, 1234w, 1207w, 1156s, 1104s, 
1063m, 1008w, 965w, 898m, 854m, 809s, 779w, 756w, 666s; 1H-NMR (DMSO-d6), δ: 11.37 (br. s, 
1H), 8.93 (d, J = 9.0 Hz, 1H), 8.61 (d, J = 7.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.94–7.90 (m, 3H), 
7.75 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 7.0 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 154.31, 143.99, 
141.18, 139.84 (q, 1JCF = 268.6 Hz), 139.32, 138.51, 127.62, 127.05 (q, 2JCF = 32.2 Hz), 127.03 (q, 
3JCF = 4.0 Hz), 126.33, 125.36, 119.48, 116.47, 101.14; HR-MS: for C16H11ClF3N2+ [M+H]+ calculated 
323.0557 m/z, found 323.0559 m/z. 
7-Chloro-4-[(2-nitrophenyl)amino]quinolinium chloride (9a). Yield 58%; Mp. 219–220 °C; IR (Zn/Se 
ATR, cm−1): 2350w, 1629w, 1583s, 1537m, 1470w, 1440m, 1420m, 1394w, 1351m, 1303s, 1204m, 
1088m, 999w, 863m, 812s, 743m; 1H-NMR (DMSO-d6), δ: 11.63 (br. s, 1H), 8.94 (d, J = 9.0 Hz, 1H), 
8.59 (d, J = 6.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 2.0 Hz, 2H), 6.88 (d, J = 7.0 Hz, 2H), 
6.59 (d, J = 6.8 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 155.32, 145.36, 143.32, 138.92, 137.69, 
135.32, 130.55, 130.09, 129.55, 127.81, 126.32, 126.22, 118.28, 115.93, 100.84; HR-MS: for 
C15H11ClN3O2+ [M+H]+ calculated 300.0534 m/z, found 300.0537 m/z. 
7-Chloro-4-[(3-nitrophenyl)amino]quinolinium chloride (9b). Yield 53%; Mp. 273–274 °C; IR (Zn/Se 
ATR, cm−1): 2637w, 1585m, 1535m, 1515s, 1442s, 1407w, 1352s, 1332m, 1235m, 1208m, 1169w, 
1092m, 908w, 850w, 811s, 775w, 735s, 718s, 687s; 1H-NMR (DMSO-d6), δ: 11.38 (br.s, 1H), 8.88 (d, 
J = 9.3 Hz, 1H), 8.63 (d, J = 7.0 Hz, 1H), 8.36 (t, J = 2.0 Hz 1H), 8.24 (ddd, J = 8.2 Hz, J = 2.3 Hz,  
J = 1.0 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 8.00–7.98 (m, 1H), 7.92 (dd, J = 9.2 Hz, J = 2.1 Hz, 1H), 
7.85 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 6.8 Hz, 1H); 13C-NMR APT (DMSO-d6), δ: 154.59, 148.68, 
144.13, 139.28, 138.62, 138.59, 131.46, 131.40 127.75, 126.27, 121.81, 119.91, 119.52, 116.44, 
101.02; HR-MS: for C15H11ClN3O2+ [M+ H]+ calculated 300.0534 m/z, found 300.0536 m/z. 
7-Chloro-4-[(4-nitrophenyl)amino]quinolinium chloride (9c). Yield 39%; Mp. 286–287 °C; IR (Zn/Se 
ATR, cm−1): 2645w, 1618m, 1583s, 1543m, 1504m, 1450m, 1377w, 1343s, 1297m, 1238m, 1211m, 
1178w, 1105m, 1095m, 996w, 917w, 854m, 832m, 803w, 744w, 694w; 1H-NMR (DMSO-d6), δ: 11.36 
(br. s, 1H), 8.87 (d, J = 9.0 Hz, 1H), 8.70 (d, J = 6.8 Hz, 1H), 8.40–8.36 (m, 1H), 8.19 (d,  
J = 2.3 Hz, 1H), 7.95–7.90 (m, 1H), 7.79–7.77 (m, 2H), 7.24 (d, J = 7.0 Hz, 1H), 6.61–6.57 (m, 1H); 
13C-NMR APT (DMSO-d6), δ: 155.80, 153.62, 144.65, 144.07, 139.73, 138.64, 127.90, 126.48, 
125.50, 124.40, 119.89, 117.09, 102.37; HR-MS: for C15H11ClN3O2+ [M+H]+ calculated 300.0534 m/z, 
found 300.0537 m/z. 
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3.3. QSAR Study 
Calculation of log P values and electronic Hammett’s σ parameters, both for the uncharged 
molecules, were carried out on the software ACD/Percepta ver. 2012 (Advanced Chemistry 
Development, Inc., Toronto, ON, Canada). Correlation and regression analyses of the QSAR study 
were run on a personal computer using the Microsoft Excel program. In the equations, the figures in 
the parentheses are the standard errors of the regression coefficients, n is the number of compounds, r 
is the correlation coefficient, F is the significance test (F-test) and s is the standard error of estimate. 
F-test values are statistically significant for all equations at 1% level of probability. 
3.4. Study of Inhibition of Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [64]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Scientific), using an artificial electron 
acceptor 2,6-dichlorophenol-indophenol (DCPIP) according to Kralova et al. [65], and the rate of 
photosynthetic electron transport was monitored as a photoreduction of DCPIP. The measurements 
were carried out in phosphate buffer (0.02 mol/L, pH 7.2) containing sucrose (0.4 mol/L), MgCl2 
(0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll content was 30 mg/L in these experiments and 
the samples were irradiated (~100 W/m2 with 10 cm distance) with a halogen lamp (250 W) using a 4 cm 
water filter to prevent warming of the samples (suspension temperature 22 °C). The studied 
compounds were dissolved in DMSO due to their limited water solubility. The applied DMSO 
concentration (up to 4%) did not affect the photochemical activity in spinach chloroplasts. The 
inhibitory efficiency of the studied compounds was expressed by IC50 values, i.e., by molar concentration 
of the compounds causing 50% decrease in the oxygen evolution rate relative to the untreated control. 
The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-dimethylurea, DCMU 
(Diurone®) was about 1.9 μmol/L. The results are summarized in Table 1. 
3.5. Study of Chlorophyll a Fluorescence in Spinach Chloroplasts 
The fluorescence emission spectra of chlorophyll a (Chla) in spinach chloroplasts were recorded on 
fluorescence spectrophotometer F-2000 (Hitachi, Tokyo, Japan) using excitation wavelength λex = 436 nm 
for monitoring fluorescence of Chla, excitation slit 20 nm and emission slit 10 nm. The samples were 
kept in the dark for 2 min before measuring. The phosphate buffer used for dilution of the chloroplast 
suspension was the same as described above. Due to low aqueous solubility the compounds were 
added to chloroplast suspension in DMSO solution. The DMSO concentration in all samples was the 
same as in the control (10%). In fluorescence experiments the chlorophyll concentration in chloroplast 
suspension was kept constant, 10 mg/L. 
3.6. In Vitro Antimycobacterial Evaluation 
As antimycobacterial screening was performed in two different institutions, two different 
procedures were used for testing. The evaluation of in vitro antimycobacterial activity of the 
compounds was performed against Mycobacterium marinum CAMP 5644, M. kansasii DSM 44162 
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and M. smegmatis ATCC 700084. The broth dilution micro-method in Middlebrook 7H9 medium 
(Difco, Lawrence, KS, USA) supplemented with BD BBL™ Middlebrook ADC Enrichment (Becton, 
Dickinson & Co., Franklin Lakes, NJ, USA) was used to determine the minimum inhibitory 
concentration (MIC) as previously described [66]. The compounds were dissolved in DMSO (Sigma-
Aldrich, Munich, Germany), and the final concentration of DMSO did not exceed 2.5% of the total 
solution composition. The final concentrations of the evaluated compounds ranging from 256 μg/mL to 
0.125 μg/mL were obtained by twofold serial dilution of the stock solution in microtiter plate with 
sterile medium. Bacterial inocula were prepared by transferring colonies from culture to sterile water. 
The cell density was adjusted to 0.5 McFarland units (1.5 × 108 cfu) using a densitometer (Densi-La-
Meter, LIAP, Riga, Latvia). The final inoculum was made by 1:1000 dilution of the suspension with 
sterile water. Drug-free controls, sterility controls and controls consisted of medium and DMSO alone 
were included. The conditions of static incubation in the darkness in an aerobic atmosphere were as 
follows: 3 days at 37 °C for M. smegmatis, 7 days at 37 °C for M. kansasii and 21 days at 28 °C for M. 
marinum, as was described recently [45,46,67,68]. 
A clinical isolate of M. avium subsp. paratuberculosis CIT03 was grown in Middlebrook broth 
(MB), supplemented with Oleic-Albumin-Dextrose-Catalase supplement (OADC, Becton, Dickinson 
& Co.) and mycobactin J (2 µg/mL). Identification of this isolate was performed using biochemical 
and molecular protocols. At log phase growth, culture (10 mL) was centrifuged at 15,000rpm/20 min 
using a bench top centrifuge (Model CR 4-12, Jouan Inc., Winchester, VA, USA). Following removal 
of the supernatant, the pellet was washed in fresh Middlebrook 7H9GC broth and re-suspended in 
fresh supplemented MB (10 mL). The turbidity was adjusted to match McFarland standard No.1  
(3 × 108 cfu) with MB broth. A further 1:20 dilution of the culture was then performed in MB broth. 
The antimicrobial susceptibility of the mycobacterial species was investigated in a 96-well plate format. 
In these experiments, sterile deionised water (300 µL) was added to all outer-perimeter wells of the 
plates to minimize evaporation of the medium in the test wells during incubation. Each evaluated 
compound (100 µL) was incubated with each of the mycobacterial species (100 µL). Dilutions of each 
compound were prepared in duplicate. For all synthesized compounds, final concentrations ranged 
from 1,000 µg/mL to 8 µg/mL. All compounds were prepared in DMSO and subsequent dilutions were 
made in supplemented MB. The plates were sealed with parafilm and incubated at 37 °C, for 11 days 
in the case of M. avium subsp. paratuberculosis. Following incubation, a 10% addition of alamarBlue 
(AbD Serotec, Kidlington, UK) was mixed into each well and readings at 570 nm and 600 nm were 
taken, initially for background subtraction and subsequently after 24 h re-incubation. The background 
subtraction is necessary for strongly coloured compounds, where the colour may interfere with the 
interpretation of any colour change. For non-interfering compounds, a blue colour in the well was 
interpreted as an absence of growth and a pink colour was scored as growth. The minimum inhibitory 
concentrations (MICs) were initially defined as the lowest concentration which prevented a visual 
colour change from blue to pink, as was described recently [15,16,41,44,46]. 
The MICs were defined as the lowest concentration of the compound at which no visible bacterial 
growth was observed. The MIC value is routinely and widely used in bacterial assays and is a standard 
detection limit according to the Clinical and Laboratory Standards Institute (CLSI). Isoniazid, 
pyrazinamide, rifampicin and ciprofloxacin (Sigma-Aldrich, Munich, Germany) were used as 
reference antimycobacterial drug. The results are summarized in Table 1. 
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3.7. In Vitro Cytotoxicity Assay 
Human monocytic leukemia THP-1 cells were obtained from the European Collection of Cell 
Cultures (ECACC, Salisbury, UK; Methods of characterization: DNA Fingerprinting (Multilocus 
probes) and isoenzyme analysis). These cells were routinely cultured in RPMI 1640 (Lonza, Verviers, 
Belgium) medium supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, Munich, 
Germany), 2% L-glutamine, 1% penicillin and streptomycin (Lonza, Verviers, Belgium) at 37 °C with 
5% CO2. Cells were passaged at approximately 1 week intervals. Cells were routinely tested for the 
absence of mycoplasma (Hoechst 33258 staining method). Cytotoxicity of the compounds was 
determined using a WST-1 assay kit (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer’s instructions. THP-1 cells were exposed for 24 h at 37 °C to various compound 
concentrations ranging from 1.25 μmol/L to 20 μmol/L in RPMI 1640 medium. For WST-1 assays, cells 
were seeded into 96-well plates (5 × 104 cells·well−1 in 100 μL culture medium) in triplicate in serum-
free RPMI 1640 medium and measurements were taken 24 h after the treatment with the compounds. 
The maximum concentration of DMSO in the assays never exceeded 0.1%. All data from three 
independent experiments were evaluated using GraphPad Prism 5.00 software (GraphPadSoftware, 
San Diego, CA, USA). The results are summarized in Table 1. 
4. Conclusions 
A series of twenty-five ring-substituted 4-arylamino-7-chloroquinolinium chlorides were prepared 
and characterized. The prepared compounds were tested for their ability to inhibit photosynthetic 
electron transport (PET) in spinach chloroplasts (Spinacia oleracea L.) and for their antimycobacterial 
activity against Mycobacterium marinum, M. kansasii, M. smegmatis and M. avium subsp. 
paratuberculosis. 7-Chloro-4-[(3-trifluoromethylphenyl)amino]quinolinium chloride (8b) showed the 
highest PET inhibition within the whole series and PET-inhibiting activity of ortho-substituted 
compounds was significantly lower than this of meta- and para-substituted ones. 
4-[(2-Bromophenyl)amino]-7-chloroquinolinium chloride (7a) showed comparatively good biological 
activity against M. marinum, M. kansasii, M. smegmatis and 7-chloro-4-[(2-methylphenyl)amino]  
quinolinium chloride (4a) demonstrated quite good biological activity against M. smegmatis and  
M. avium subsp. paratuberculosis. Both compounds showed comparable or higher activity than the 
standard isoniazid. It can be stated that lipophilicity and especially electronic properties of aniline 
substituents influenced the biological activities of compounds. The dependences of antimycobacterial 
efficacy in particular on electronic properties showed bilinear trends with the σ optimum 0.22 for  
M. marinum and M. kansasii, and with the σ optimum −0.17 for M. smegmatis and M. avium subsp. 
paratuberculosis. None of the tested compounds were cytotoxic in the highest available concentration used 
in these cytotoxicity assays (LD50 > 20 μmol/L). 
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